KCTD21 Inhibitors

KCTD21 inhibitors encompass a variety of chemical compounds that interact with different cellular pathways, ultimately leading to the inhibition of KCTD21. Proteasome inhibitors like MG-132 and Bortezomib function by impeding the degradation of ubiquitinated proteins, potentially leading to the accumulation of inactive, polyubiquitinated forms of KCTD21. On the other hand, lysosomal pH modulators, such as Hydroxychloroquine and Chloroquine, disrupt lysosomal function, which could indirectly impair the degradation or recycling pathways critical for KCTD21 function.

Proteasome Inhibitors such as MG-132 and Bortezomib work by preventing the proteasomal degradation of ubiquitinated proteins. This can lead to an accumulation of proteins within the cell, including potentially inactive, polyubiquitinated forms of KCTD21. The buildup of such proteins can interfere with various cellular functions and may result in the diminished activity of KCTD21 if it is normally targeted for degradation through this pathway.